Eterna Therapeutics Inc. (NASDAQ:ERNA) Sees Large Increase in Short Interest

Eterna Therapeutics Inc. (NASDAQ:ERNA) was the recipient of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 348,200 shares, an increase of 86.6% from the February 13th total of 186,600 shares. Based on an average daily volume of 10,510,000 shares, the short-interest ratio is presently 0.0 days. Approximately 1.8% of the company’s shares are sold short.

Eterna Therapeutics Stock Performance

Shares of Eterna Therapeutics stock traded up $0.00 during trading on Friday, hitting $0.26. The company’s stock had a trading volume of 176,871 shares, compared to its average volume of 13,049,398. The company has a fifty day simple moving average of $0.35 and a two-hundred day simple moving average of $0.72. The company has a market capitalization of $1.39 million, a PE ratio of -0.03 and a beta of 4.47. Eterna Therapeutics has a 52 week low of $0.22 and a 52 week high of $2.63.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Eterna Therapeutics stock. Geode Capital Management LLC increased its holdings in Eterna Therapeutics Inc. (NASDAQ:ERNA) by 1,159.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 257,310 shares of the company’s stock after acquiring an additional 236,875 shares during the quarter. Geode Capital Management LLC owned about 4.76% of Eterna Therapeutics worth $76,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 70.55% of the company’s stock.

Eterna Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.